n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Thursday, March 9th, 2017

The QualityStocks
Daily Stock List

graphic
graphic

HedgePath Pharmaceuticals, Inc. (HPPI)

BUYINS.NET reported on HedgePath Pharmaceuticals, Inc. (HPPI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

HedgePath Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It discovers, develops, and plans to commercialize ground-breaking therapeutics for patients with cancer. The Company is looking to repurpose the Food and Drug Administration (FDA) approved antifungal pharmaceutical itraconazole as a potential treatment for cancer. HedgePath Pharmaceuticals has its headquarters in Tampa, Florida.

The Company is the exclusive U.S. licensee of a patented formulation of itraconazole, called SUBA-Itraconazole. Clinical studies have shown it to have greater bioavailability than generic itraconazole. The Hedgehog signaling pathway is a major regulator of cellular processes in vertebrates. This includes cell differentiation, tissue polarity, as well as cell proliferation.  

HedgePath Pharmaceuticals believes (based on published research) that inhibiting the Hedgehog pathway could delay or possibly prevent the development of certain cancers in humans. Leveraging research undertaken by key investigators in the field, the Company’s plan is to explore the effectiveness of SUBA-Itraconazole as an anti-cancer agent and to pursue its potential commercialization.  

The design of “SUBA technology” (which stands for “super bioavailability”) is to improve the bioavailability of orally administered drugs that are poorly soluble. SUBA-Itraconazole is a patented formulation developed by Mayne Pharma. It has improved absorption and substantially reduced variability in comparison to generic itraconazole.

In October 2016, HedgePath Pharmaceuticals announced further positive interim data from its continuing, open-label Phase II(b) clinical trial studying the effect of SUBA-Itraconazole (SUBA-Cap) oral capsules in patients with Basal Cell Carcinoma Nevus Syndrome (BCCNS) - Gorlin Syndrome. BCCNS results from a genetic mutation that causes the Hedgehog pathway (a major regulator of processes in cells) to function improperly, leading to the chronic formation of basal cell tumors.

Eighteen subjects with Basal Cell Carcinoma Nevus Syndrome who had 231 surgically eligible tumors completed 16 weeks of dosing with SUBA™-Itraconazole. Second interim analysis shows a statistically significant mean target tumor burden reduction (P<0.0001) and 11 of 18 trial subjects to date realizing a 30 percent or greater reduction in target tumor burden.

Industry sources estimate that there are roughly 10,000 patients in the U.S. with BCCNS. This has qualified SUBA-Itraconazole under the FDA's Orphan Drug Designation Program.

This past December, HedgePath Pharmaceuticals announced that its shares of common stock were approved for trading on the OTCQX U.S. market. The Company’s stock commenced trading on the OTCQX, effective December 8, 2016, under the ticker symbol "HPPI."

HedgePath Pharmaceuticals, Inc. (HPPI), closed Thursday's trading session at $0.34, even for the day, on 3,914 volume with 5 trades. The average volume for the last 60 days is 9,435 and the stock's 52-week low/high is $0.1102/$0.6548.

Mymetics Corp. (MYMX)

TopPennyStockMovers and The Dean reported previously on Mymetics Corp. (MYMX), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Mymetics Corp. is a biotechnology company whose shares trade on the OTCQB. Mymetics is developing next-generation preventative vaccines for infectious diseases. Its corporate vision is to become the market leader in the development of new generation mucosal and virosomes based vaccines. Mymetics has a Research Lab in the Netherlands. The Company’s core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Mymetics is based in Epalinges, Switzerland.

The Company currently has a group of vaccines in its pipeline: HIV-1/AIDS, intra-nasal Influenza, Malaria, Chikungunya, Herpes Simplex Virus, and the RSV vaccine. The design of its vaccines is to induce protection against early transmission and infection, centering on the mucosal immune response as a first-line defense that for some pathogens, may be critical for the development of an effective prophylactic vaccine. The HIV, malaria, and intra-nasal influenza vaccines have successfully finished Phase 1 clinical trials; the others are in the pre-clinical phase.

Mymetics is concentrating on developing pioneering preventative vaccines utilizing two key scientific approaches. One is Virosomes as an effective adjuvant and a vaccine delivery method, and the other is innovative antigen design through generating mucosal antibodies.

Through centering on these two scientific approaches, Mymetics’ strategy is addressing two important needs in developing effective vaccines. One is the ability to build a first line of defense against viruses entering the blood stream through focusing on the mucosal layer. The other is the development of a new vaccine delivery platform that doesn’t use live attenuated or killed pathogens, while increasing the immunogenicity and stability of the vaccine. The Company’s innovative approach is undergoing validation via partnerships with foremost pharmaceutical or research organizations.

Mymetics announced in September 2016 the continuation of the collaboration with the Texas Biomedical Research Institute related to the Mymetics' HIV vaccine candidate. The next phase of the continued collaboration will focus on the initial strong protection provided by the vaccine candidate in the study. In addition, the next phase will carefully analyze the possible mechanisms of the initial vaccine action and learn what other immune defenses can be recruited to yield even more potent antiviral action.

Mymetics’ subsidiary, Mymetics B.V., has agreed on a research project with Sanofi Pasteur, the vaccine division of Sanofi (SNY). The project will investigate the immunogenicity of influenza vaccines based on Mymetics' proprietary virosome technology platform in pre-clinical settings.

Mymetics has gained a unique research and development (R&D) expertise, specialist knowledge, and intellectual property (IP) rights directly related to virosome based vaccines. This makes the Company the worldwide leader in this field. Mymetics’ team comprise the original inventors of the virosome technology, which is a platform that can be adapted to numerous vaccines.

Mymetics Corp. (MYMX), closed Thursday's trading session at $0.0201, up 0.50%, on 15,898 volume with 3 trades. The average volume for the last 60 days is 108,463 and the stock's 52-week low/high is $0.008/$0.08.

WhiteFox Ventures, Inc. (AWAW)

We are highlighting WhiteFox Ventures, Inc. (AWAW) today, here at the QualityStocks Daily Newsletter.

WhiteFox Ventures, Inc. is a diversified financial services and technology company listed on the OTC Markets Group’s OTCQB. The Company focuses on its revenue generating investor academy, and also building a strong balance sheet via the strategic investment of its proprietary capital. WhiteFox operates in nine locations in Japan. These locations are Sapporo, Sendai, Tokyo, Matsumoto, Nagoya, Osaka, Okayama, Kumamoto and Fukuoka. WhiteFox Ventures has offices in Tokyo, Japan, and New York, New York.

Fundamentally, WhiteFox Ventures is an educational company. WhiteFox teaches its students or members the art of making money and self-improving methods for a better life. The Company teaches its members varied methods for making money from real estate, stocks, and crypto currencies. The Company’s teachers come from different sectors.

In 2016, WhiteFox Ventures announced that it executed an agreement to invest $2,500,000 into NQ Minerals, PLC. NQ Minerals is an Australian mining company. WhiteFox Ventures believes this to be a wise investment and portrays Company Management's confidence and commitment in today's worldwide market for gold and silver as viable investment options, while simultaneously significantly reinforcing its underlying balance sheet.

NQ Minerals concentrates on projects where past exploration work has established the presence of mineral occurrences. NQ Minerals’ management team has decades of experience in the exploration and production of gold, silver, and also an array of base metals.

NQ Minerals is concentrating on two exploration projects called Ukalunda and Square Post, in North Queensland, Australia. The projects are both in prospective mining districts that form part of the well-known Charters Towers Gold Province, where more than 20 million ounces of gold has been mined.

WhiteFox Ventures will continue to consider potential investments as its Board of Directors believes practical. The Company’s Board determined that its long-term business strategy will focus on potential acquisitions as the primary driver of shareholder value. WhiteFox is evaluating several sectors from which to consider prospective acquisitions. WhiteFox also plans to expand its revenue generating academy business in Asia as the basis to fund balance sheet investments and other potential acquisitions currently considered.

Mr. Shinsuke Nakano is the Chief Executive Officer of WhiteFox Ventures. Mr. Nakano founded AXS Company, Ltd. in 2008, which focused on the production of infomercials and TV programs and reported profitability within 2 years ($1.7 million during the first year and $4.2 million during the second year). Subsequently, he started a venture capital business that he still focuses amounts of time building. Mr. Nakano is very experienced in complex business negotiations and structuring funding instruments for public and private companies.

WhiteFox Ventures, Inc. (AWAW), closed Thursday's trading session at $0.1245, up 159.38%, on 100 volume with 1 trade. The average volume for the last 60 days is 10,206 and the stock's 52-week low/high is $0.0051/$0.30.

Advanced Environmental Petroleum Producers, Inc. (AEPP)

We are highlighting Advanced Environmental Petroleum Producers, Inc. (AEPP) today, here at the QualityStocks Daily Newsletter.

Advanced Environmental Petroleum Producers, Inc. is working to become an oil and gas exploration and development company, operating in Peru. The Company has a number of targets in the highly prospective Block 19 of the southern region of the country. After eight years of research and development (R&D), the Company has led the effort to begin exploring close to three million acres of the Peruvian resources. Advanced Environmental Petroleum Producers (AEPP) is based in Las Vegas, Nevada.

AEPP, upon completing a Technical Evaluation Agreement (TEA), will hold an exclusive license, which entitles it to explore and develop certain oil and gas properties called "Block 19." This is an area of 10,100 square km. AEPP’s mission is to extract hydrocarbons employing the most advanced environmental technologies available. The Company’s emphasis is Peruvian environmental sustainable oil & gas development.

AEPP says that it has developed (through a technology partnership with PointSource Processing) the most advanced environmental process for extracting Oil & Gas resources with minimal damage to the environment. The process enables it to reinstate the ground as it develops, to leave minimal to no scaring. The processed areas undergo conversion into engineered farm land for the local communities.

The Company has an Independent Peruvian Engineer’s Technical Report that qualified and quantified the assets. The deposits contain conventional/shale Oil & Gas. Furthermore, there are no tailings or contaminated stock piles. The expectation is that the production cost will be competitive to North American standards.

On December 14, 2016, AEPP announced that it received the acceptance of its Technical Evaluation Agreement (TEA) for Block 19 Certificate of Qualification No. W GGRL-CC-19-2016 under the qualification of oil companies approved by Supreme Decree W 030-2004-EM and amended by Supreme Decree W 001-2012-EM by PeruPetroS.A. permitting the implementation of convention's Technical Evaluation of Block19.

AEPP’s Chief Technology Officer, Mr. Nigel Bosworth, stated, "AEPP can now instruct Chapman Petroleum Engineers from Calgary Alberta Canada to proceed on site to complete the 51-101 Petroleum Reserve Report for Block 19."

AEPP is clear to go on to manufacture and install the full Pilot Plant from its exclusive Technology supplier Pointsource Processing (PSP) for the extraction of gas and oil from Block 19.

Advanced Environmental Petroleum Producers, Inc. (AEPP), closed Thursday's trading session at $0.0111, up 0.91%, on 404,677 volume with 19 trades. The average volume for the last 60 days is 508,138 and the stock's 52-week low/high is $0.007/$0.50.

GrowGeneration Corp. (GRWG)

We are highlighting GrowGeneration Corp. (GRWG) today, here at the QualityStocks Daily Newsletter.

GrowGeneration Corp. is one of the largest specialty retail hydroponic and organic gardening store chains. The Company sells to the commercial and home cannabis markets. GrowGeneration is an online and offline resource for professional growers. Its intention is to be a grow pioneer's single-source outfitter for the latest in first-rate growing products, options, ideas and more. GrowGeneration’s mission is to own and operate GrowGeneration branded stores in all the major legalized cannabis states.

The Company carries and sells thousands of products. These include organic nutrients and soils, and advanced lighting technology. Products also include state-of-the-art hydroponic equipment to be used indoors and outdoors by commercial and home growers.

GrowGeneration announced this past November that it signed a 5-year lease on a 10,000-square foot facility in Las Vegas, Nevada (its 12th store). This location will be a retail and warehouse location. It will serve the increasing number of commercial and home growers in the Nevada market.

In January 2017, GrowGeneration announced that it and New Frontier Data partnered to provide cultivators in the sector with the necessary data to help them better understand where their time, resources, and money should be spent to best align with product demand and maximize profitability at a crucial time in this developing sector. New Frontier Data is the authority in real time business intelligence for the cannabis industry. GrowGeneration will provide historical and real time sales data to New Frontier Data to create a "State of the Ancillary Market" report to be released for sale in the first half of this year.

GrowGeneration earlier announced that its Las Vegas store officially opened its doors on January 17, 2017. Moreover, the Company separately announced that it is one of 11 companies recently added to MJIC's Marijuana Index. At present, GrowGeneration has 10 locations in Colorado, 1 location in California, and 1 location in Las Vegas, Nevada.

At the beginning of February, GrowGeneration announced that it signed a 5-year lease on a 13,000-square foot facility in Denver, Colorado for its 12th store. The Denver South location will serve as a retail and warehouse location, and also the Company's corporate headquarters. It will serve the growing number of commercial and home growers in the Denver market.

Additionally, GrowGeneration entered into a 5-year lease for a 7,300-sq. ft. facility in Trinidad, Colorado that will replace and consolidate its existing 3,000 sq. ft. Trinidad store as the Company's new center for the Trinidad and New Mexico markets.

Furthermore, GrowGeneration recently announced that it acquired all of the assets of Sonoma Hydro. The Company signed a 5-year lease on an 8,000-square foot facility in Santa Rosa, California. The Sonoma Hydro location, one of the original hydroponic stores in what is called the Emerald Triangle, will serve as a retail and warehouse location serving the growing number of commercial and home growers in the Northern California market.

GrowGeneration Corp. (GRWG), closed Thursday's trading session at $1.88, up 1.08%, on 7,907 volume with 26 trades. The average volume for the last 60 days is 31,379 and the stock's 52-week low/high is $1.50/$3.43.

graphic

The QualityStocks
Company Corner

graphic
graphic

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.0675, up 10.66%, on 6,302,172 volume with 366 trades. The stock’s average daily volume over the past 60 days is 9,197,691, and its 52-week low/high is $0.0055/$0.142.

Singlepoint, Inc. announced today that a new audio interview with the Company is now available. The interview can be heard at http://smallcapvoice.com/blog/3-8-17-smallcapvoice-interview-with-singlepoint-inc-sing. Greg Lambrecht, CEO of SinglePoint Inc., called in to SmallCapVoice.com to provide the listening audience with an update on all the Company’s progress here in 2017 as well as his personal insights into the growth of the industries that company operates in. Recently, SinglePoint announced that the Company has raised more than $600,000 and is optimistic that they will secure additional funding of $1 million.

Singlepoint, Inc. (SING) provides mobile technology and marketing solutions that enable companies, nonprofits and religious organizations to conduct business transactions, accept donations, and engage in targeted communication via mobile devices. Through diversification of its own model, the company is also leveraging its core technology to expand into the mobile auctions and daily fantasy sports markets.

SING currently has two fundraising solutions. Text2Bid is an interactive way to increase auction revenues. The technology makes it easy for people to bid in auctions from any text or web-enabled phone. Donate by Text allows nonprofits to securely collect one-time or recurring donations via text. This capability creates a personal experience for the donors, and enables ongoing communication between the donor and nonprofit or event sponsor.

SING's payment solutions include point-of-sale (POS) terminals, loyalty programs, payment processing, phone services and financing. Pay by Text™ enables a business to accept payment transactions and, in essence, turns the user's mobile phone into a point-of-sale device. Operating on the same platform as mobile marketing, Pay by Text is designed to increase revenues, raise the average per-transaction amount, and create a fast, easy and hassle-free method of payment.

As part of its diversification and expansion strategy, SING recently acquired an interest in DraftFury (www.draftfury.com), a company that offers skill-based NBA, NFL and MLB daily fantasy sports (DFS) contests. DraftFury is known for its innovative offerings and originality, and is the first cash-flow-positive DFS enterprise. This transaction places SING in a multi-billion dollar industry expected to generate entry fees of $14.4 billion in 2020. Under the guidance of a leadership team well-versed in technology, engineering, marketing and raising capital, SING anticipates a strong foothold in its chosen markets. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

Greg Lambrecht, CEO of SinglePoint Inc., Discusses Recent SING News and Industry Trends in A New Audio Interview withSmallCapVoice.com

Singlepoint Takes a Low Risk Approach to the Cannabis Industry -- CFN Media

SinglePoint, Inc. Featured on MoneyTV with Donald Baillargeon, 2/17

Stealth Technologies Inc. (STTH)

The QualityStocks Daily Newsletter would like to spotlight Stealth Technologies Inc. (STTH). Today, Stealth Technologies Inc. closed trading at $0.044, up 25.71%, on 360,828 volume with 19 trades. The stock’s average daily volume over the past 60 days is 30,720, and its 52-week low/high is $0.015/$0.05.

Founded in 1999, Stealth Technologies Inc. (STTH) is focused on developing and marketing products that deliver cost effective, independently validated solutions for large addressable international and domestic markets. The company's primary target is identity protection and personal safety.

The Stealth Card represents the company's flagship solution for identity protection. Today there are more than 1.5 billion credit and debit cards in circulation with RFID chips, making it easier than ever for identity thieves to steal sensitive information without contact. The paper-thin Stealth Card offered by Stealth Technologies protects up to 12 RFID credit cards in a wallet without any batteries or charging requirements.

StealthIdentityTheft.com is an expansion of the company's commitment to provide first-rate identity protection solutions. The proprietary system underlying this identity protection and recovery service was designed in partnership with law enforcement officials. Utilizing the most effective methods of prevention involving a two-step process, StealthIdentityTheft.com is a superior answer to the non-stop identity theft taking place every day.

The international marketplace was infiltrated by Stealth Technologies when the company launched its 911 HELP NOW™ emergency medical alert device. Providing direct access with 911 service at a touch of a button, the device is packed with powerful features including a full year of battery life from standard AAA batteries, compact ergonomic design, 2-way voice and a durable, splash resistant design.

Stealth Mobile is the latest product offering introduced to leverage the Stealth Technologies' brand and sales channels established by the other products. Similar to the Stealth Card, Stealth Mobile prevents electronic pickpocketing. The product guards NFC transmissions emitted by cell phone devices, which can include personal information, messages and financial data.

Stealth Technologies recognizes the value of the rapid sales growth generated by these technologies and has multiple patents pending to safeguard its investments. With an expanding product suite and ongoing expansion into the identity theft protection marketplace, Stealth Technologies remains committed to its focus on increased growth and profitability. Disclaimer

Stealth Technologies Inc. Company Blog

Stealth Technologies Inc. News:

Stealth Technologies Announces 5 New Products

Stealth Technologies Highlights Opportunities from Attendance at Leading Real Estate, Home Staging Conference

NetworkNewsWire Releases Exclusive Audio Interview with Stealth Technologies, Inc. (STTH)

InMed Pharmaceuticals, Inc. (IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.2601, up 5.30%, on 372,342 volume with 130 trades. The stock’s average daily volume over the past 60 days is 823,224, and its 52-week low/high is $0.05/$0.4261.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Pharmaceuticals Files PCT Patent for Epidermolysis Bullosa Simplex

InMeds Bioinformatics Platform Powers Cannabinoid Drug Development -- CFN Media

InMed Receives over $1,350,000 From Warrant Exercise

GreenStone Healthcare Corp. (GRST)

The QualityStocks Daily Newsletter would like to spotlight GreenStone Healthcare Corp. (GRST). Today, GreenStone Healthcare Corp. closed trading at $0.0439, up 4.77%, on 27,860 volume with 4 trades. The stock’s average daily volume over the past 60 days is 63,129, and its 52-week low/high is $0.015/$0.083.

GreenStone Healthcare Corp. (GRST), developed and ran a first class addiction treatment center in Muskoka. Ontario. Greenestone recently restructured by selling its Muskoka treatment center business, purchasing the underlying real estate of the treatment center and leasing it to the purchasers.  It also purchased  a treatment center business and real estate in Delray Beach, Florida. GreenStone will not compete in the Canadian marketplace and focus on the much larger US market for addiction treatment.  Greenestone is uniquely qualified to bring its well honed practices to the US marketplace and can thrive in the current challenging environment of substance addictions.

GreeneStone employs the best principles and practices currently available in the treatment of individuals with addiction. To ensure the most comprehensive and effective treatment for its clients, GreenStone treats underlying or co-occurring disorders in tandem with the treatment of addiction.

The 36-bed addiction treatment center offers a holistic, individualized treatment approach to recovery. These private, paid programs vary in length from 45-90 days, depending on the unique needs of each resident and their response to the treatment.

GreenStone also provides education and counseling sessions to educate the family members of its residents with the objective of helping them better understand the disease of addiction and how they should support their loved one throughout and after their recovery efforts.

GreenStone Healthcare President Shawn Leon has more than 25 years of experience managing public and private development-stage companies for various industries, including industrial minerals, aggregates, oil and gas, mining, financial, technology, hospitality and medical. He has provided financing and capital markets oversight for a number of these ventures, many of which have involved negotiations for mergers and acquisitions. He is joined by Vice President Dr. Anita Teslak, whose 25 years of combined experience as a CEO, psychologist and leadership provides valuable insight into a successful business model. Disclaimer

GreenStone Healthcare Corp. Company Blog

GreenStone Healthcare Corp. News:

GreeneStone Buys Canadian Real Estate Assets, Sells Canadian Addiction Treatment Business, and Acquires Addiction Treatment Business in Florida

GreeneStone Signs Definitive Agreement to Acquire Seastone of Delray, a Florida Limited Liability Company

GreeneStone Signs LOI to Acquire Aurora Recovery

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.68, up 4.58%, on 146,273 volume with 88 trades. The stock’s average daily volume over the past 60 days is 44,567 and its 52-week low/high is $0.05/$2.09.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

NetworkNewsWire Releases Exclusive Audio Interview with ORHub, Inc. (ORHB)

ORhub, Inc. (ORHB) Engages NetworkNewsWire for Corporate Communications Solutions

ORHub, Inc. (ORHB) Expands Operations at Nation's Second Largest Non-Profit Hospital System

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

QualityStocks
(AWAW) +159.38%

2.

PennyPickGains
(DTGI) +104.00%

3.

Fortune Stock Alerts
(EMAV) +75.00%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251